Cyclophosphamide Dosing for Interstitial Lung Disease
For systemic autoimmune rheumatic disease-associated ILD (particularly SSc-ILD), cyclophosphamide should be dosed as either 500-750 mg/m² IV every 4 weeks for 6 months OR 2 mg/kg/day orally (maximum 100-200 mg/day) for 6 months, with the IV route preferred due to better tolerability. 1
Dosing Regimens by Route
Intravenous Cyclophosphamide
- Dose: 500-750 mg/m² IV every 4 weeks
- Duration: 6 months total treatment
- Monitoring: CBC with differential at 10-14 days after each administration and just before the next dose; urinalysis every 4-8 weeks 1
Oral Cyclophosphamide
- Starting dose: 50-150 mg per day
- Target dose: 2 mg/kg/day (maximum 100-200 mg/day depending on expert preference)
- Duration: 6 months total treatment
- Monitoring: CBC with differential at 10-14 days after starting and after any dose increase; every 4 weeks on stable dosing; urinalysis every 4-8 weeks 1
Critical Monitoring Requirements
Baseline assessments must include CBC with differential and urinalysis before initiating therapy 1. The FDA label specifies that cyclophosphamide should not be administered when neutrophils are ≤1,500/mm³ or platelets <50,000/mm³ 2.
Long-term surveillance: Once treated with cyclophosphamide, annual urine cytology is required indefinitely due to bladder cancer risk 1.
Hydration Protocol
Adequate fluid intake or infusion must be provided during or immediately after administration to force diuresis and reduce urinary tract toxicity risk. Oral cyclophosphamide should be taken in the morning to allow daytime voiding 2.
Evidence Base and Nuances
The 2024 ACR/CHEST guidelines provide the strongest evidence framework for SARD-ILD treatment 1. For SSc-ILD specifically, the 2024 ATS guideline addresses cyclophosphamide use, though it notes that studies did not separate efficacy by route of administration 3. The landmark trials (SLS I and SLS II) used oral cyclophosphamide at 2 mg/kg/day for 12 months, but current guidelines recommend 6-month duration to balance efficacy with toxicity 3.
Important caveat: For idiopathic pulmonary fibrosis (IPF) specifically, cyclophosphamide has shown limited efficacy and is not recommended 4, 5. The evidence supporting cyclophosphamide is primarily for autoimmune-associated ILD, not idiopathic forms.
Common Pitfalls
- Fertility counseling is mandatory before starting therapy; cyclophosphamide causes infertility in both sexes 1, 2
- Pregnancy avoidance requires effective contraception during treatment and for 1 year after completion in females, 4 months in males 2
- Hemorrhagic cystitis risk necessitates aggressive hydration and morning dosing for oral formulations 1
- Marrow suppression is dose-limiting; dose adjustments based on nadir counts are essential 2
When to Avoid or Modify
Cyclophosphamide is contraindicated in patients with urinary outflow obstruction 2. Treatment should be interrupted or dose-reduced in patients who develop serious infections 2. The 2024 ACR/CHEST guidelines strongly recommend against long-term glucocorticoids in SSc-ILD and conditionally recommend against them in other SARD-ILD when disease progresses despite first-line therapy 1.